

SensiQuant Sars-Cov-2

Detection and Quantification of RNA
from purified extracts and thermolysis of
nasopharyngeal swabs



Monoreagent format Real time PCR One-Step

Qualitative or Quantitative Assay

High sensitivity and specificity

Easy results interpretation


Detection of N1 + N2 regions

Endogenous control

Validation on NP swabs crude thermolysates

SensiQuant Sars-Cov-2

Detection and Quantification of RNA from purified extracts and thermolysis of nasopharyngeal swabs



COVID-19

2019-NCOV

NOVEL CORONAVIRUS

NCP

SensiQuant Sars-Cov-2 is the Bioclarma kit for qualitative and quantitative research of SARS-Cov-2 RNA that combines high sensitivity and specificity performance with robustness and simplicity in the interpretation of results.

Direct One-step RT-PCR Amplification from crude lysates of nasopharyngeal swabs without the need of further purification.

Amplification system based on the co-amplification in a single reaction of the N1 + N2 region of the viral genome and of the human RP gene.

SensiQuant Sars-Cov-2 Standard provides serial dilutions of plasmids to be used for a quantitative standards curve or as qualitative controls.

SensiQuant Sars-Cov-2 - available products

Ref.	Description	Format
SQT-044	SensiQuant Sars-Cov-2 Master Mix Detection and quantification of Sars-Cov-2 RNA 460 Qualitative test or 450 Quantitative tests	480 reactions
STD-044	SensiQuant Sars-Cov-2 Standard <i>Plasmidic standard for N1+N2 regions and endogenous control RP</i> 20 Quantitative runs or 40 Qualitative runs	20/40 runs



Bioclarma srl
Operations: Via Nizza, 52 - 10126 TORINO - ITALIA
Legal Office & Operations: Via F. Petrarca 4/F - 10126 TORINO - ITALIA VAT IT09506040014
Tel. +39-011-188-944-74 Fax +39-011-670-84-16
E-mail: info@bioclarma.com Web: www.bioclarma.com